Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Limited-stage ovarian carcinoma.

J T Thigpen1

  • 1Department of Medicine, University of Mississippi Medical Center, Jackson 39216, USA.

Seminars in Oncology
|July 13, 2000
PubMed
Summary

Currently, no effective ovarian cancer screening exists, leading to late-stage diagnoses. Risk stratification after surgery guides treatment, with chemotherapy significantly reducing recurrence in high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical trials in gynecological cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Same author

Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics·2001
Same author

[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].

Gynecologie, obstetrique & fertilite·2000
Same author

Chemotherapy for advanced ovarian cancer: overview of randomized trials.

Seminars in oncology·2000
Same author

The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same author

CA 15-3 and c-erbB-2 presence in the saliva of women.

Clinical oral investigations·2000

Area of Science:

  • Gynecologic Oncology
  • Surgical Pathology
  • Clinical Oncology

Background:

  • Ovarian carcinoma diagnosis lacks effective screening, resulting in advanced-stage disease at presentation for most patients.
  • Early-stage ovarian cancer (FIGO stages I-II) still carries a significant risk of recurrence, necessitating risk stratification.
  • Current management strategies differentiate between low-risk and high-risk early-stage disease.

Purpose of the Study:

  • To define criteria for risk stratification in early-stage ovarian carcinoma.
  • To outline optimal management strategies based on risk categorization.
  • To evaluate the impact of adjuvant chemotherapy on recurrence rates.

Main Methods:

  • Retrospective analysis of early-stage ovarian carcinoma cases.
  • Categorization of patients into low-risk and high-risk groups based on histopathological and clinical features.
  • Comparison of recurrence rates between observation and adjuvant chemotherapy in high-risk groups.

Main Results:

  • Low-risk early-stage ovarian carcinoma (grade I, confined to ovary, negative cytology, no ascites) has >90% 5-year disease-free survival with surgery and observation.
  • High-risk early-stage ovarian carcinoma (grade 2-3, extra-ovarian spread, positive cytology, or ascites) has approximately 40% recurrence rate.
  • Platinum-based adjuvant chemotherapy reduced recurrence rates by half compared to no adjuvant therapy in high-risk patients.

Conclusions:

  • Risk stratification is crucial for managing early-stage ovarian carcinoma.
  • Surgical resection followed by observation is adequate for low-risk disease.
  • Adjuvant platinum-based chemotherapy is recommended for high-risk early-stage ovarian carcinoma to reduce recurrence.

Related Experiment Videos